Literature DB >> 24918319

Fecal biomarkers in the diagnosis and monitoring of Crohn's disease.

Emily K Wright1, Peter De Cruz, Richard Gearry, Andrew S Day, Michael A Kamm.   

Abstract

The diagnosis and monitoring of Crohn's disease has traditionally relied on clinical assessment, serum markers of inflammation, and endoscopic examination. Fecal biomarkers such as calprotectin, lactoferrin, and S100A12 are predominantly derived from neutrophils, are easily detectable in the feces, and are emerging as valuable markers of intestinal inflammation. This review focuses on the role of fecal biomarkers in the diagnosis and monitoring of Crohn's disease, in particular how these biomarkers change with disease activity and remission, how they can be used to monitor the response to medical therapy, their value in predicting clinical relapse, and their role in monitoring the postoperative state.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24918319     DOI: 10.1097/MIB.0000000000000087

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

Review 1.  Utility of Biomarkers in the Management of Inflammatory Bowel Disease.

Authors:  Gursimran Kochhar; Bret Lashner
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

2.  Targeting Mucosal Healing in Crohn's Disease.

Authors:  Michael F Picco; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-10

3.  Elevated fecal calprotectin levels during necrotizing enterocolitis are associated with activated neutrophils extruding neutrophil extracellular traps.

Authors:  B C MacQueen; R D Christensen; C C Yost; D K Lambert; V L Baer; M J Sheffield; P V Gordon; M J Cody; E Gerday; R Schlaberg; J Lowe; J G Shepherd
Journal:  J Perinatol       Date:  2016-07-07       Impact factor: 2.521

Review 4.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

5.  Expression and clinical implication of S100A12 in gastric carcinoma.

Authors:  Dan Li; Zhi Zeng; Tao Yu; Jian Qin; Jie Wu; Jin-Chun Song; Zi-Ying Zhou; Jing-Ping Yuan
Journal:  Tumour Biol       Date:  2015-12-05

6.  Association of clinical characteristics and lifestyle factors with fecal S100/calgranulin concentrations in healthy dogs.

Authors:  Romy M Heilmann; Melissa M Guard; Linda Toresson; Stefan Unterer; Aurélien Grellet; Niels Grützner; Jan S Suchodolski; Joerg M Steiner
Journal:  Vet Med Sci       Date:  2021-03-10

7.  Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

Authors:  Vivian W Huang; Connie Prosser; Karen I Kroeker; Haili Wang; Carol Shalapay; Neil Dhami; Darryl K Fedorak; Brendan Halloran; Levinus A Dieleman; Karen J Goodman; Richard N Fedorak
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

8.  Non-invasive identification of protein biomarkers for early pregnancy diagnosis in the cheetah (Acinonyx jubatus).

Authors:  Diana C Koester; David E Wildt; Morgan Maly; Pierre Comizzoli; Adrienne E Crosier
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

9.  Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study.

Authors:  Takahiro Shimoyama; Takayuki Yamamoto; Satoru Umegae; Koichi Matsumoto
Journal:  Therap Adv Gastroenterol       Date:  2017-07-04       Impact factor: 4.409

Review 10.  Biomarkers in Search of Precision Medicine in IBD.

Authors:  Ray K Boyapati; Rahul Kalla; Jack Satsangi; Gwo-Tzer Ho
Journal:  Am J Gastroenterol       Date:  2016-09-27       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.